ArticleFrontiers in oncology2022

A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Yuan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.